The identified signature genes (RPS13, MRPS5, MRPL21, MRPL22, NDUFS3) not only unravel the molecular cascade linking maternal hyperglycemia to fetal vascular dysfunction but also offer tangible targets for diagnostic and therapeutic innovation. This evidence concerns the gene MRPL22 and Hyperglycemia.